journal article·2025-01-22

Zebrafish as a Visible Neuroinflammation Model for Evaluating the Anti-Inflammation Effect of Curcumin-Loaded Ferritin Nanoparticles

Jiamao Chen, Haidong Zha, Meng Xu, Shuli Li, Yunfeng Han, Qinyu Li, Wei Ge, Simon Ming-Yuen Lee, Yong Gan, Ying Zheng

Publisher page

Abstract

It is crucial to inhibit the neuroinflammation response as it is a prominent factor contributing to the pathogenesis of neurodegenerative disorders. However, the limited development of neuroinflammation models dramatically hinders the efficiency of nanomedicine discovery. In recent years, the optically transparent zebrafish model provided unique advantages for in vivo imaging of the whole body, allowing the progression of the disease to be visualized. In this study, a lipopolysaccharide (LPS)-mediated zebrafish neuroinflammation model was established to visualize the brain distribution and quickly evaluate the anti-inflammation effect of human ferritin-loaded curcumin (Cur@HFn) nanoparticles. The Cur@HFn drug delivery system was successfully prepared and characterized. The HFn nanocage demonstrated significant brain accumulation and prolonged circulation in a zebrafish larval model. In the LPS-induced zebrafish model, Cur@HFn significantly reduced neutrophil recruitment within the brain region of the LPS-treated zebrafish. Additionally, Cur@HFn mitigated nitric oxide (NO) release and downregulated the mRNA expression levels of proinflammatory cytokines, including TNF-α and IL-1β. Lastly, Cur@HFn significantly reduced the damage of raphe nucleus neurons and alleviated the locomotion deficiency caused by LPS. Overall, our findings highlight that Cur@HFn is a promising drug delivery system for the targeted treatment of brain disorders. This zebrafish neuroinflammation model could be used for high-throughput in vivo drug screening and discovery.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Zebrafish Biomedical Research Applications · Neuroinflammation and Neurodegeneration Mechanisms · Phagocytosis and Immune Regulation

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Taipa, Macau 999078, China

State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China

School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, China

Department of Biomedical Sciences and Centre of Reproduction, Development and Aging (CRDA), Faculty of Health Sciences, University of Macau, Taipa, Macau 999078, China

Department of Food Science and Nutrition, The Hong Kong Polytechnic University, Hong Kong 999077, China

University of Chinese Academy of Sciences, Beijing 100049, China

NMPA Key Laboratory for Quality Research and Evaluation of Pharmaceutical Excipients, National Institutes for Food and Drug Control, Beijing 100050, China

Department of Pharmaceutical Sciences, Faculty of Health Sciences, University of Macau, Taipa, Macau 999078, China

MoE Frontiers Science Center for Precision Oncology, University of Macau, Taipa, Macau 999078, China

Funding

Universidade de Macau · Shenzhen Science and Technology Innovation Commission · Fundo para o Desenvolvimento das Ci??ncias e da Tecnologia · Guangdong Institute for Drug Control

References (41)

Show source-provided references
1. 10.1021/acschemneuro.0c0042710.1021/acschemneuro.0c00427 ↗
2. 10.1016/S1474-4422(15)70016-510.1016/S1474-4422(15)70016-5 ↗
3. 10.1186/s40035-015-0042-010.1186/s40035-015-0042-0 ↗
4. 10.1016/j.cnr.2006.09.00410.1016/j.cnr.2006.09.004 ↗
5. 10.1038/nri.2016.12310.1038/nri.2016.123 ↗
6. 10.1124/jpet.108.13745510.1124/jpet.108.137455 ↗
7. 10.1016/j.molimm.2019.09.02010.1016/j.molimm.2019.09.020 ↗
8. 10.1016/j.cell.2015.10.06710.1016/j.cell.2015.10.067 ↗
9. 10.1016/j.jconrel.2023.05.00910.1016/j.jconrel.2023.05.009 ↗
10. 10.1038/s41573-021-00139-y10.1038/s41573-021-00139-y ↗
11. 10.1002/wnan.122110.1002/wnan.1221 ↗
12. 10.1073/pnas.091319210710.1073/pnas.0913192107 ↗
13. 10.1021/acsbiomedchemau.2c0000310.1021/acsbiomedchemau.2c00003 ↗
14. 10.1021/bm200026v10.1021/bm200026v ↗
15. 10.1021/acsnano.7b0696910.1021/acsnano.7b06969 ↗
16. 10.1186/s12951-022-01474-x10.1186/s12951-022-01474-x ↗
17. 10.3389/fcell.2020.0032810.3389/fcell.2020.00328 ↗
18. 10.1016/j.parkreldis.2017.07.02710.1016/j.parkreldis.2017.07.027 ↗
19. 10.1016/j.addr.2019.04.00910.1016/j.addr.2019.04.009 ↗
20. 10.1038/nrd244610.1038/nrd2446 ↗
21. 10.1002/VIW.2023002510.1002/VIW.20230025 ↗
22. 10.1016/j.brainresbull.2007.10.04310.1016/j.brainresbull.2007.10.043 ↗
23. 10.1016/j.ydbio.2019.03.00510.1016/j.ydbio.2019.03.005 ↗
24. 10.1038/nature1211110.1038/nature12111 ↗
25. 10.1038/nrd462710.1038/nrd4627 ↗
26. 10.1016/j.addr.2019.01.00110.1016/j.addr.2019.01.001 ↗
27. 10.1177/019262331140959710.1177/0192623311409597 ↗
28. 10.1016/j.phrs.2017.08.01710.1016/j.phrs.2017.08.017 ↗
29. 10.1021/acsami.7b1280910.1021/acsami.7b12809 ↗
30. 10.1016/j.biomaterials.2020.12018010.1016/j.biomaterials.2020.120180 ↗
31. 10.1016/j.nantod.2022.10145010.1016/j.nantod.2022.101450 ↗
32. 10.1002/smll.20210358410.1002/smll.202103584 ↗
33. 10.1021/acsami.2c0900510.1021/acsami.2c09005 ↗
34. 10.3791/64313-v10.3791/64313-v ↗
35. 10.1016/j.nantod.2020.10094810.1016/j.nantod.2020.100948 ↗
36. 10.1016/0022-1759(90)90029-u10.1016/0022-1759(90)90029-u ↗
37. 10.1038/s41598-019-44569-610.1038/s41598-019-44569-6 ↗
38. 10.1016/j.foodres.2014.05.05410.1016/j.foodres.2014.05.054 ↗
39. 10.1021/acs.biomac.7b0097410.1021/acs.biomac.7b00974 ↗
40. 10.1080/10717544.2022.205666210.1080/10717544.2022.2056662 ↗
41. 10.1016/S1386-1425(03)00342-110.1016/S1386-1425(03)00342-1 ↗